220 related articles for article (PubMed ID: 30038380)
1. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Leeksma AC; Taylor J; Wu B; Gardner JR; He J; Nahas M; Gonen M; Alemayehu WG; Te Raa D; Walther T; Hüllein J; Dietrich S; Claus R; de Boer F; de Heer K; Dubois J; Dampmann M; Dürig J; van Oers MHJ; Geisler CH; Eldering E; Levine RL; Miller V; Mughal T; Lamanna N; Frattini MG; Heaney ML; Zelenetz A; Zenz T; Abdel-Wahab O; Kater AP
Leukemia; 2019 Feb; 33(2):390-402. PubMed ID: 30038380
[TBL] [Abstract][Full Text] [Related]
2. A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.
Amin NA; Seymour E; Saiya-Cork K; Parkin B; Shedden K; Malek SN
Clin Cancer Res; 2016 Sep; 22(17):4525-35. PubMed ID: 27060156
[TBL] [Abstract][Full Text] [Related]
3. Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression.
Sutton LA; Rosenquist R
Expert Rev Hematol; 2015 Feb; 8(1):71-8. PubMed ID: 25345442
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
5. Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study.
Ramassone A; D'Argenio A; Veronese A; Basti A; Soliman SHA; Volinia S; Bassi C; Pagotto S; Ferracin M; Lupini L; Saccenti E; Balatti V; Pepe F; Rassenti LZ; Innocenti I; Autore F; Marzetti L; Mariani-Costantini R; Kipps TJ; Negrini M; Laurenti L; Visone R
J Hematol Oncol; 2019 Nov; 12(1):114. PubMed ID: 31744508
[TBL] [Abstract][Full Text] [Related]
6. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.
Malcikova J; Stano-Kozubik K; Tichy B; Kantorova B; Pavlova S; Tom N; Radova L; Smardova J; Pardy F; Doubek M; Brychtova Y; Mraz M; Plevova K; Diviskova E; Oltova A; Mayer J; Pospisilova S; Trbusek M
Leukemia; 2015 Apr; 29(4):877-85. PubMed ID: 25287991
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing.
Vollbrecht C; Mairinger FD; Koitzsch U; Peifer M; Koenig K; Heukamp LC; Crispatzu G; Wilden L; Kreuzer KA; Hallek M; Odenthal M; Herling CD; Buettner R
PLoS One; 2015; 10(6):e0129544. PubMed ID: 26053404
[TBL] [Abstract][Full Text] [Related]
8. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
9. Gene mutations in chronic lymphocytic leukemia.
Amin NA; Malek SN
Semin Oncol; 2016 Apr; 43(2):215-21. PubMed ID: 27040699
[TBL] [Abstract][Full Text] [Related]
10. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
11. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
Blakemore SJ; Clifford R; Parker H; Antoniou P; Stec-Dziedzic E; Larrayoz M; Davis Z; Kadalyayil L; Colins A; Robbe P; Vavoulis D; Forster J; Carr L; Morilla R; Else M; Bryant D; McCarthy H; Walewska RJ; Steele AJ; Chan J; Speight G; Stankovic T; Cragg MS; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Schuh A; Strefford JC
Leukemia; 2020 Jul; 34(7):1760-1774. PubMed ID: 32015491
[TBL] [Abstract][Full Text] [Related]
13. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.
Brieghel C; da Cunha-Bang C; Yde CW; Schmidt AY; Kinalis S; Nadeu F; Andersen MA; Jacobsen LO; Andersen MK; Pedersen LB; Delgado J; Baumann T; Mattsson M; Mansouri L; Rosenquist R; Campo E; Nielsen FC; Niemann CU
Clin Cancer Res; 2020 Mar; 26(6):1507-1515. PubMed ID: 31919133
[TBL] [Abstract][Full Text] [Related]
14. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.
Jethwa A; Hüllein J; Stolz T; Blume C; Sellner L; Jauch A; Sill M; Kater AP; te Raa GD; Geisler C; van Oers M; Dietrich S; Dreger P; Ho AD; Paruzynski A; Schmidt M; von Kalle C; Glimm H; Zenz T
Br J Haematol; 2013 Nov; 163(4):496-500. PubMed ID: 24032483
[TBL] [Abstract][Full Text] [Related]
15. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.
Barrio S; Shanafelt TD; Ojha J; Chaffee KG; Secreto C; Kortüm KM; Pathangey S; Van-Dyke DL; Slager SL; Fonseca R; Kay NE; Braggio E
Leukemia; 2017 Jan; 31(1):170-176. PubMed ID: 27469216
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
Nadeu F; Clot G; Delgado J; Martín-García D; Baumann T; Salaverria I; Beà S; Pinyol M; Jares P; Navarro A; Suárez-Cisneros H; Aymerich M; Rozman M; Villamor N; Colomer D; González M; Alcoceba M; Terol MJ; Navarro B; Colado E; Payer ÁR; Puente XS; López-Otín C; López-Guillermo A; Enjuanes A; Campo E
Leukemia; 2018 Mar; 32(3):645-653. PubMed ID: 28924241
[TBL] [Abstract][Full Text] [Related]
17. Examination of clonal evolution in chronic lymphocytic leukemia.
Koczkodaj D; Popek-Marciniec S; Zmorzyński S; Wąsik-Szczepanek E; Filip AA
Med Oncol; 2019 Aug; 36(9):79. PubMed ID: 31375939
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.
Sutton LA; Rosenquist R
Haematologica; 2015 Jan; 100(1):7-16. PubMed ID: 25552678
[TBL] [Abstract][Full Text] [Related]
19. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.
Ojha J; Ayres J; Secreto C; Tschumper R; Rabe K; Van Dyke D; Slager S; Shanafelt T; Fonseca R; Kay NE; Braggio E
Blood; 2015 Jan; 125(3):492-8. PubMed ID: 25377784
[TBL] [Abstract][Full Text] [Related]
20. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
Hu B; Patel KP; Chen HC; Wang X; Wang F; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating MJ; Wierda WG
Br J Haematol; 2019 Jun; 185(5):852-864. PubMed ID: 30924136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
